Boston Scientific
Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.
TheraSphere holds FDA approval for HCC (2021) and is studied in EPOCH (colorectal liver metastases, positive PFS) and combination trials with immunotherapy; also drug-eluting embolic beads and interventional oncology devices.
Pages like this
not linked directly; found by shared links- CompanySirtex Medical
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Colorectal cancer.
- TrialSARAH and SIRveNIB
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- TrialEMERALD-1
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TrialLEAP-012
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma, Colorectal cancer.
- TermDownstaging and conversion therapy
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma, Colorectal cancer.
- IdeaReprogramme the liver's own immune cells to refuse metastases
Shares Radioembolisation (TARE / SIRT, yttrium-90), Colorectal cancer.
- TrialEMERALD-3
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.